Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors, at American Society of Clinical Oncology (ASCO) Annual Meeting

BEVERLY, MA–(Marketwired – May 28, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announced that the Company will be sponsoring an abstract publication at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 – June 2, 2015 at McCormick Place in Chicago, Illinois. The poster will provide an overview of the Company’s ongoing Phase 1 clinical trial of Kevetrin as a monotherapy for advanced solid tumors being conducted at Harvard Cancer Centers’ Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center and will include information on the activation of p53 through inducing p21 gene expression. The poster will be presented during the poster session titled, “Developmental Therapeutics — Clinical Pharmacology and Experimental Therapeutics” in S Hall A.

Details of the poster presentation:

Saturday May 30, 2015 from 8:00 AM to 11:30 AM CDT

Title: A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors

Presenter: Geoffrey Shapiro, MD, PhD. – Director, Early Drug Development Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School

Location: S Hall A

Poster Board Number: Board #323a

Abstract No: TPS2613

Category: Developmental Therapeutics — Clinical Pharmacology and Experimental Therapeutics

Sub-category: Cytotoxics and other Novel Agents

Citation: J Clin Oncol 33, 2015 (suppl; abstr TPS2613)

The link on the ASCO website is: http://abstracts.asco.org/156/AbstView_156_149817.html

“The Poster at ASCO is a meaningful advancement in the progression of Kevetrin as we look towards Phase 2 trials to further evaluate our novel compound’s effect on p53 in solid and liquid tumors,” commented Krishna Menon, Chief Scientific Officer at Cellceutix. “We are pleased to once again present at ASCO. We believe the interest in Cellceutix has never been greater.”

Following the presentation at ASCO, Cellceutix will make the poster available on its website.